NovoCure Limited · NASDAQ:NVCR
NovoCure — Q3 2023 Earnings Presentation
14 slides from NovoCure's earnings presentation, October 2023
Slide 1: © s oO & = = AW = ise) ror
© s 2 oO & = = AW = ise) ror
Slide 2: Forward-looking statements
novocure forward-looking statements In addition to historical facts or statements of current condition, this presentation may contain forward-looking statements. Forward-looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding a
Slide 3: A comprehensive strategy for long-term growth
novecure’ a comprehensive strategy for long-term growth drive awareness and advance deliver commercial adoption clinical trials product innovation in approved to reach new patient to increase dose and indications populations duration of therapy Built upon a foundation of financial strength and a rob
Slide 4: Enrollment complete and pivotal data anticipated in multiple phase 3 trials by year-end 2024
novecure’ enrollment complete and pivotal data anticipated in multiple phase & trials by year-end 2024 an) LUNAR METIS | PANOVA-3 Lung Cancer Brain Metastasis Pancreatic Cancer TRIAL COMPLETE MET PRIMARY ENDPOINT ENROLLMENT COMPLETE ENROLLMENT COMPLETE * Patients treated with TTFields + ¢ Evaluating
Slide 5: Phase 3 LUNAR trial met primary overall survival endpoint
novecure’ phase 5 LUNAR trial met primary overall survival endpoint Overall survival (ITT population) Overall survival (ICl-treated patients) 10 1.0 09 09 Median OS (months) 13.2 9.9 Median OS (months) 18.5 10.8 08 Log-rank P-value 0.035 08 Log-rank P-value 0.03 <= 07 HR (95% Ci) 0.74 (0.56-0.98) 07
Slide 6: Growing foundation of pre-clinical and clinical research supporting the use of TTFields
novecure’ growing foundation of pre-clinical and clinical research supporting the use of TT Fields CLINICAL JOURNAL PUBLICATIONS MEDICAL CONGRESS PRESENTATIONS ‘The Effect of Body Mass Index (BMI) on Tumor Treating Fields JAR® (Fields) Intensity Distribution in the Lungs TTFields and Immune-Checkpoi
Slide 7: Ongoing commercial pathway to treat NSCLC patients
novecure’ ongoing commercial pathway to treat NSCLC patients 0 2023 5 2024 2025 L COMMERCIAL LAUNCH * Activate physici d REGULATORY PATHWAY CiehieTSS [pIMA/STCHEIN Gn patient education CLINICAL DATA v Initiate pre-PMA discussions programs y, ; with FDA * Treat on-protocol patients ABOUTISSS (eyllnts
Slide 8: New lighter, thinner arrays deliver greater intensity
novecure’ new lighter, thinner arrays deliver greater intensity an EXISTING ARRAYS NEW ARRAYS AP channel, 1,364 mAmps AP channel, 1,685 mAmps OV/cm NCHED IN GERMANY patientforward © 2023Novocure GmbH 8 Array performance data obtained from pati
Slide 9: Q3 2023 selected financial highlights
novecure’ qs 2023 selected financial highlights U.S. DOLLARS IN THOUSANDS Q3 2023 Q3 2022 % CHANGE Net revenues $ 127,321 = $ 130,988 -3% Cost of revenues 32,092 29,749 8% Gross profit 95,229 101,249 -6% Research, development and clinical trials 53,623 51,956 3% Sales and marketing 57,964 41,395 40%
Slide 10: Together with our patients, we strive to extend survival
together with our patients, we strive to extend survival in some of the most aggressive forms of cancer Bs gr patientforward” © 2023N
Slide 11: Optune Lua and Optune indications for use and important safety information
novecure’ Optune Lua® and Optune® indications for use and important safety information INDICATIONS Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of a
Slide 12: Optune Lua and Optune indications for use and important safety information
novecure’ Optune Lua® and Optune® indications for use and important safety information WARNINGS AND PRECAUTIONS » Optune and Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®. * The most common (210%) adverse event
Slide 13: Appendix
appendix patient
Slide 14: Adjusted EBITDA reconciliation
novocure adjusted EBITDA reconciliation Adjusted EBITDA is a non-GAAP measurement of earnings before interest, taxes, depreciation, amortization and share-based compensation. We believe Adjusted EBITDA is useful to investors in evaluating our operating performance because it helps investors compare